COLISTINA EN EL TRATAMIENTO DE INFECCIONES POR PSEUDOMONAS AERUGINOSA Y ACINETOBACTER BAUMANNII EXTENSIVAMENTE RESISTENTES (XDR) EN UN HOSPITAL DE TERCER NIVEL
Objective: To describe the clinical response and overall mortality of Colistin in infections by Pseudomonas XDR and Acinetobacter XDR at the Hospital Nacional Arzobispo Loayza in Lima, Peru. Methods: Observational, descriptive, retrospective study. Records of all patients > 18 years old, from...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Asociación Colombiana de Infectología
2020-06-01
|
Series: | Infectio |
Subjects: | |
Online Access: | https://www.revistainfectio.org/index.php/infectio/article/view/876 |
id |
doaj-544e2866839f459a83106d547c826e1e |
---|---|
record_format |
Article |
spelling |
doaj-544e2866839f459a83106d547c826e1e2020-11-25T03:54:39ZengAsociación Colombiana de InfectologíaInfectio0123-93922020-06-0124420120710.22354/in.v24i4.876COLISTINA EN EL TRATAMIENTO DE INFECCIONES POR PSEUDOMONAS AERUGINOSA Y ACINETOBACTER BAUMANNII EXTENSIVAMENTE RESISTENTES (XDR) EN UN HOSPITAL DE TERCER NIVEL Eddie Angles-Yanqui0https://orcid.org/0000-0002-0602-384XServicio de Infectología. Hospital Nacional Arzobispo Loayza. Lima. Perú. Profesor de la Universidad Peruana Cayetano Heredia, Lima, Perú. Objective: To describe the clinical response and overall mortality of Colistin in infections by Pseudomonas XDR and Acinetobacter XDR at the Hospital Nacional Arzobispo Loayza in Lima, Peru. Methods: Observational, descriptive, retrospective study. Records of all patients > 18 years old, from June 2014 to June 2016, who had infection by Pseudomonas XDR or Acinetobacter XDR confirmed by culture, and who received colistin, were included. A univariate analysis of the general characteristics of the patients was performed; a bivariate analysis with a Chi2, t-student or ANOVA test as appropriate, and the factors associated with mortality were also determined. Results: 56 patient records were included; the median age was 46,5 [31,5 to 63,5]. The Culture was positive for Pseudomonas XDR in 48,2% and for Acinetobacter XDR in 51,8%. The favorable clinical response was 85,7% at 15 days and 78,6% at 30 days. In-hospital mortality at 30 days was 21,4%, ICU mortality was 30,8% and nephrotoxicity was 5,4%. Conclusions: Colistin combined with another antimicrobial had a favorable clinical response in infection with Pseudomonas XDR and Acinetobacter XDR. https://www.revistainfectio.org/index.php/infectio/article/view/876colistinacinetobacterpseudomonas aeruginosagram-negative bacteria (source: mesh nlm) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eddie Angles-Yanqui |
spellingShingle |
Eddie Angles-Yanqui COLISTINA EN EL TRATAMIENTO DE INFECCIONES POR PSEUDOMONAS AERUGINOSA Y ACINETOBACTER BAUMANNII EXTENSIVAMENTE RESISTENTES (XDR) EN UN HOSPITAL DE TERCER NIVEL Infectio colistin acinetobacter pseudomonas aeruginosa gram-negative bacteria (source: mesh nlm) |
author_facet |
Eddie Angles-Yanqui |
author_sort |
Eddie Angles-Yanqui |
title |
COLISTINA EN EL TRATAMIENTO DE INFECCIONES POR PSEUDOMONAS AERUGINOSA Y ACINETOBACTER BAUMANNII EXTENSIVAMENTE RESISTENTES (XDR) EN UN HOSPITAL DE TERCER NIVEL |
title_short |
COLISTINA EN EL TRATAMIENTO DE INFECCIONES POR PSEUDOMONAS AERUGINOSA Y ACINETOBACTER BAUMANNII EXTENSIVAMENTE RESISTENTES (XDR) EN UN HOSPITAL DE TERCER NIVEL |
title_full |
COLISTINA EN EL TRATAMIENTO DE INFECCIONES POR PSEUDOMONAS AERUGINOSA Y ACINETOBACTER BAUMANNII EXTENSIVAMENTE RESISTENTES (XDR) EN UN HOSPITAL DE TERCER NIVEL |
title_fullStr |
COLISTINA EN EL TRATAMIENTO DE INFECCIONES POR PSEUDOMONAS AERUGINOSA Y ACINETOBACTER BAUMANNII EXTENSIVAMENTE RESISTENTES (XDR) EN UN HOSPITAL DE TERCER NIVEL |
title_full_unstemmed |
COLISTINA EN EL TRATAMIENTO DE INFECCIONES POR PSEUDOMONAS AERUGINOSA Y ACINETOBACTER BAUMANNII EXTENSIVAMENTE RESISTENTES (XDR) EN UN HOSPITAL DE TERCER NIVEL |
title_sort |
colistina en el tratamiento de infecciones por pseudomonas aeruginosa y acinetobacter baumannii extensivamente resistentes (xdr) en un hospital de tercer nivel |
publisher |
Asociación Colombiana de Infectología |
series |
Infectio |
issn |
0123-9392 |
publishDate |
2020-06-01 |
description |
Objective: To describe the clinical response and overall mortality of Colistin in infections by Pseudomonas XDR and Acinetobacter XDR at the Hospital Nacional
Arzobispo Loayza in Lima, Peru.
Methods: Observational, descriptive, retrospective study. Records of all patients > 18 years old, from June 2014 to June 2016, who had infection by Pseudomonas
XDR or Acinetobacter XDR confirmed by culture, and who received colistin, were included. A univariate analysis of the general characteristics of the patients was performed; a bivariate analysis with a Chi2, t-student or ANOVA test as appropriate, and the factors associated with mortality were also determined.
Results: 56 patient records were included; the median age was 46,5 [31,5 to 63,5]. The Culture was positive for Pseudomonas XDR in 48,2% and for Acinetobacter
XDR in 51,8%. The favorable clinical response was 85,7% at 15 days and 78,6% at 30 days. In-hospital mortality at 30 days was 21,4%, ICU mortality was 30,8% and nephrotoxicity was 5,4%.
Conclusions: Colistin combined with another antimicrobial had a favorable clinical response in infection with Pseudomonas XDR and Acinetobacter XDR.
|
topic |
colistin acinetobacter pseudomonas aeruginosa gram-negative bacteria (source: mesh nlm) |
url |
https://www.revistainfectio.org/index.php/infectio/article/view/876 |
work_keys_str_mv |
AT eddieanglesyanqui colistinaeneltratamientodeinfeccionesporpseudomonasaeruginosayacinetobacterbaumanniiextensivamenteresistentesxdrenunhospitaldetercernivel |
_version_ |
1724472465627807744 |